Final NICE rejection for Biomarin’s childhood rare disease drugAfter a year of negotiations NICE has confirmed that it is still unable to recommend Biomarin’s Batten disease Share XFinal NICE rejection for Biomarin’s childhood rare disease drughttps://pharmaphorum.com/news/final-nice-rejection-for-biomarins-childhood-rare-disease-drug/
Mendelian gets £500,000 for rare disease screening techUK health technology startup Mendelian has received a £500,000 grant from a government agency to build products that Share XMendelian gets £500,000 for rare disease screening techhttps://pharmaphorum.com/news/mendelian-gets-500000-for-rare-disease-screening-tech/
Merck adds to I-O stable with $300m Immune Design buyJust a few months after Immune Design saw its shares crater on a phase II fail, Merck & Share XMerck adds to I-O stable with $300m Immune Design buyhttps://pharmaphorum.com/news/merck-adds-to-i-o-stable-with-300m-immune-design-buy/
Novo Nordisk and Abbott announce digital diabetes tie-upNovo Nordisk and devices firm Abbott have announced a partnership that aims to make diabetes management easier by Share XNovo Nordisk and Abbott announce digital diabetes tie-uphttps://pharmaphorum.com/news/novo-nordisk-and-abbott-announced-digital-diabetes-tie-up/
Brexit could disrupt medicine supplies for six months – ministerA no-deal Brexit could disrupt medicines supplies to the UK for at least six months because of delays Share XBrexit could disrupt medicine supplies for six months – ministerhttps://pharmaphorum.com/news/brexit-could-disrupt-medicine-supplies-for-six-months-minister/
Patients switch to lower dose of Pfizer’s RA pill after safety signalPfizer is moving rheumatoid arthritis patients to a lower dose of its blockbuster inflammatory diseases pill Xeljanz in Share XPatients switch to lower dose of Pfizer’s RA pill after safety signalhttps://pharmaphorum.com/news/patients-switch-to-lower-dose-of-pfizers-ra-pill-after-safety-signal/
More positive results for Pfizer/Lilly’s non-opioid pain drugPfizer and Eli Lilly have announced more positive results from a phase 3 study of their non-opioid pain Share XMore positive results for Pfizer/Lilly’s non-opioid pain drughttps://pharmaphorum.com/news/more-positive-results-for-pfizer-lillys-non-opioid-pain-drug/
Vical slashes staff after culling phase II antifungalUS biotech Vical is planning another round of job cuts after deciding to abandon its antifungal drug VL-2397, Share XVical slashes staff after culling phase II antifungalhttps://pharmaphorum.com/news/vical-staff-culling-phase-ii-antifungal/
Makara Health promotes Katie Bright to directorKatie Bright has joined the leadership team at Makara Health, following her promotion to director at the UK-based Share XMakara Health promotes Katie Bright to directorhttps://pharmaphorum.com/news/makara-health-katie-bright/
Lisa Druce joins Lucid’s Lighthouse as managing partnerLighthouse Medical Communications US has appointed Lisa Druce as its new managing partner. She joins the New York-based Share XLisa Druce joins Lucid’s Lighthouse as managing partnerhttps://pharmaphorum.com/news/lisa-druce-lucid-lighthouse/
2.5m Australians opt out of My Health Record schemeMore than 2.5 million Australians have opted out of the country’s controversial My Health Record scheme, according to Share X2.5m Australians opt out of My Health Record schemehttps://pharmaphorum.com/news/2-5m-australians-opt-out-of-my-health-record-scheme/
UK biotech gets grant for further trial of osteoarthritis drugUK biotech AKL Research and Development (AKLRD) has received a grant from a UK government-backed innovation body to Share XUK biotech gets grant for further trial of osteoarthritis drughttps://pharmaphorum.com/news/uk-biotech-gets-grant-for-further-trial-of-osteoarthritis-drug/
AbbVie’s JAK inhibitor upadacitinib gets Priority ReviewAbbVie’s attempts to diversify beyond Humira have been boosted as its investigational drug upadacitinib has been granted Priority Share XAbbVie’s JAK inhibitor upadacitinib gets Priority Reviewhttps://pharmaphorum.com/news/abbvies-jak-inhibitor-upadacitinib-gets-priority-review/
No US launch until 2020 for Novo’s new haemophilia therapyThe US regulator has approved Novo Nordisk’s long-acting therapy for haemophilia A, Esperoct, as the Danish pharma seeks Share XNo US launch until 2020 for Novo’s new haemophilia therapyhttps://pharmaphorum.com/news/no-us-launch-until-2020-for-novos-new-haemophilia-therapy/
Keytruda gets okay from FDA for adjuvant melanomaThe US FDA has approved Merck & Co’s Keytruda as an adjuvant treatment for patients with melanoma who Share XKeytruda gets okay from FDA for adjuvant melanomahttps://pharmaphorum.com/news/keytruda-gets-okay-from-fda-for-adjuvant-melanoma/
MHRA investigates opioid regulation as addiction crisis deepensThe UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has convened an Expert Working Group (EWG) to assess Share XMHRA investigates opioid regulation as addiction crisis deepenshttps://pharmaphorum.com/news/mhra-investigates-opioid-regulation-as-addiction-crisis-deepens/
Two new cancer Priority Reviews for RocheRoche has announced that the FDA has granted Priority Review to two of its drugs – personalised lung Share XTwo new cancer Priority Reviews for Rochehttps://pharmaphorum.com/news/two-new-cancer-priority-reviews-for-roche/
Cipla taps Wellthy for digital therapeutics expertiseIndian pharma company Cipla has made another play in the digital medicine category by taking a near-12% stake Share XCipla taps Wellthy for digital therapeutics expertisehttps://pharmaphorum.com/news/cipla-taps-wellthy-for-digital-therapeutics-expertise/
J+D and the University of Bath School of Management Collaborate Share XJ+D and the University of Bath School of Management Collaboratehttps://pharmaphorum.com/partner-content/jd-and-the-university-of-bath-school-of-management-collaborate/
Pre-Filled Syringes – Chemical Compatibility and Design Strategies Share XPre-Filled Syringes – Chemical Compatibility and Design Strategieshttps://pharmaphorum.com/partner-content/pre-filled-syringes-chemical-compatibility-and-design-strategies/
SMi’s Pharma Microbiology West Coast 2019 chair and speakers announced Share XSMi’s Pharma Microbiology West Coast 2019 chair and speakers announcedhttps://pharmaphorum.com/partner-content/smis-pharma-microbiology-west-coast-2019-chair-and-speakers-announced/
Exclusive insights into the latest innovations at Drug Discovery Chemistry Share XExclusive insights into the latest innovations at Drug Discovery Chemistryhttps://pharmaphorum.com/partner-content/exclusive-insights-into-the-latest-innovations-at-drug-discovery-chemistry/
pharmaphorum welcomes George Underwood to its editorial helm Share Xpharmaphorum welcomes George Underwood to its editorial helmhttps://pharmaphorum.com/news/pharmaphorum-welcomes-george-underwood-to-its-editorial-helm/
STEM Healthcare appoints Jason McKenna as CEO Share XSTEM Healthcare appoints Jason McKenna as CEOhttps://pharmaphorum.com/partner-content/stem-healthcare-appoints-jason-mckenna-as-ceo/
